Spironolactone

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 79, Issue , 2001, Pages 319-337

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746019676     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (85)

1. American Hospital Formulary Service (2000) AHFS Drug Information® 2000, Bethesda, MD, American Society of Health-System Pharmacists [AHFSfirst CD-ROM]
2. Anon. (2000) Top generic drugs by prescription in 1999. Drug Topics, 144
3. British Pharmacopoeia Commission (1993) British Pharmacopoeia 1993, Vols I & II, London, Her Majesty's Stationery Office, pp. 627-628, 1111-1112
4. Budavari, S., ed. (2000) The Merck Index, 12th Ed., Version 12:3, Whitehouse Station, NJ, Merck & Co. & Boca Raton, FL, Chapman & Hall/CRC [CD-ROM]
5. Caminos-Torres, R., Ma, L. & Snyder, P.J. (1977) Gynecomastia and semen abnormalities induced by spironolactone in normal men. J. din. Endocrinol. Metab., 45, 255-260
6. Catania, V.A., Luquita, M.G, Sänchez Pozzi, E.J. & Mottino, A.D. (1998) Differential induction of glutathione S-transferase subunits by spironolactone in rat liver, jejunum and colon. Life Sci., 63, 2285-2293
7. Chung, W.G & Buhler, D.R. (1994) The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs. Toxicol. appl. Pharmacol., 127, 314-319
8. CIS Information Services (2000a) Directory of World Chemical Producers (Version 2000.1), Dallas, TX [CD-ROM]
9. CIS Information Services (2000b) Worldvide Bulk Drug Users Directory (Version 2000), Dallas, TX [CD-ROM]
10. Colby, H.D., O'Donnell, J.P., Flowers, N.L., Kossor, D.C., Johnson, P.B. & Levitt, M. (1991) Relationship between covalent binding to microsomal protein and the destruction of adrenal cytochrome P-450 by spironolactone. Toxicology, 67, 143-154
11. Corazza, M., Strumia, R., Lombardi, A.R. & Virgili, A. (1996) Allergic contact dermatitis from . spironolactone. Contact Derm., 35, 365-366
12. Council of Europe (1997) European Pharmacopoeia, 3rd Ed., Strasbourg, pp. 1538-1539
13. Danielson, D.A., Jick, H., Hunter, J.R, Stergachis A. & Madsen, S. (1982) Nonestrogenic drugs and breast cancer. Am. J. Epidemiol., 116, 329-332
14. Decker, C., Sugiyama, K., Underwood, M. & Correia, M.A. (1986) Inactivation of rat hepatic cytochrome P-450 by spironolactone. Biochem. biophys. Res. Commun., 136, 1162-1169
15. Decker, C.J., Hashed, M.S., Baillie, T.A., Maltby, D. & Correia, M.A. (1989) Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450. Biochemistry, 28, 5128-5136
16. Feller, D.R. & Gerald, M.C. (1971) Stimulation of liver microsomal drug metabolism in male and female mice by spironolactone and aldadiene. Proc. Soc. exp. Biol. Med., 136, 1347-1350
17. Ferguson, I., Fogg, C. & Baughan, P. (1993) Spironolactone induced agranulocytosis [Letter to the Editor]. Med. J. Aust., 159, 837
18. Friedman, G.D. & Ury, H.K. (1980) Initial screening for carcinogenicity of commonly used drugs. J. natl Cancer Inst., 65, 723-733
19. Friedman, G.D. & Ury, H.K. (1983) Screening for possible drug carcinogenicity: second report of findings. J. natl Cancer Inst., 71, 1165-1175
20. Fujita, S., Uesugi, T., Ohta, M. & Kitani, K. (1982) Effect of spironolactone on hepatic microsomal monooxygenase and azoreductase activities. Res. Commun, ehem. Pathol. Pharmacol, 36, 87-103
21. Funder, J.W., Feldman, D., Highland, E. & Edelman, I.S. (1974) Molecular modifications of anti-aldosterone compounds: Effects on affinity of spirolactones for renal aldosterone receptors. Biochem. Pharmacol., 23, 1493-1501
22. Gardiner, P., Schrode, K., Quinlan, D., Martin, B.K., Boreham, D.R., Rogers, M.S., Stubbs, K., Smith, M. & Karim, A. (1989) Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. J. din. Pharmacol., 29, 342-347
23. Gennaro, A.R. (1995) Remington: The Science and Practice of Pharmacy, 19th Ed., Vol. II, Easton, PA, Mack Publishing Co., p. 1048
24. Greenblatt, D.J. & Koch-Weser, J. (1973) Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. J. Am. med. Assoc., 225, 40-43
25. Guibert, E.E., Morisoli, L.S., Monti, J.A. & Rodriguez Garay, E.A. (1983) Effect of spironolactone on p-nitrophenol glucuronidation in isolated rat hepatocytes. Experientia, 39, 527-528
26. Hardman, J.G, Limbird, L.E., Molinoff, P.B., Ruddon, R.W. & Gillman, A.G, eds (1996) Goodman & Gilman 's, The Pharmacological Basis of Therapeutics, 9th Ed., New York, McGraw-Hill, pp. 707-709
27. IARC (1980) IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 24, Some Pharmaceutical Drugs, Lyon, lARCPress, pp. 259-273
28. IARC (1987) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, Lyon, lARCPress, p. 344
29. Institute Nacional de Farmacia e do Medicamento (2000) Lisbon Irish Medicines Board (2000) Dublin
30. Jaussan, V., Lamarchand-Béraud, T. & Gómez, F. (1985) Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol. Reprod., 32, 1051-1061
31. Jeunemaitre, X., Kreft-Jais, C., Chatellier, G, Julien, J., Degoulet, P., Plouin, P.-R, Ménard, J. & Corvol, P. (1988) Long-term experience of spironolactone in essential hypertension. Kidney int., 34, Suppl. 26, S14-S17
32. Jivraj, K.T., Noseworthy, T.W., Friesen, E.G, Shustack, A.S., Konopad, E.M. & Johnston, R.G. (1987) Spironolactone-induced agranulocytosis. Drug Intell, clin. Pharm., 21, 974-975
33. Karim, A., Zagarella, J., Hribar, J. & Dooley, M. (1976a) Spironolactone. I. Disposition and metabolism. Clin. Pharmacol. Thai:, 19, 158-169
34. Karim, A., Zagarella, J., Hutsell, T.C., Chao, A. & Baltes, B.J. (1976b) Spironolactone. II. Bioavailability. Clin. Pharmacol. Ther., 19, 170-176
35. Karim, A., Kook, C., Zitzewitz, D.J., Zagarella, J., Doherty, M. & Campion, J. (1976c) Species differences in the metabolism and disposition of spironolactone. Drug Metab. Disposition, 4, 547-555
36. van der Klauw, M.M., Wilson, J.H. & Stricker, B.H. (1998) Drug-associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am. J. Hematol, 57, 206-211
37. Kourounakis, P.N. & Tani, E. (1995) Effect of phenobarbital, spironolactone and pregnenolone-16 α-carbonitrile on rat hepatic β-glucuronidase. Res. Commun, mol. Pathol. Pharmacol., 88, 119-122
38. Kovacs, K. & Somogyi, A. (1970) Suppression by spironolactone of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors. Eur. J. Cancer, 6, 195-201
39. 4 metabolism. J. vet. Med. Sci., 62, 606-614
40. Lumb, G, Newberne, P., Rust, J.H. & Wagner, B. (1978) Effects in animals of chronic administration of spironolactone -A review. J. environ. Pathol. Toxicol., 1, 641-660
41. McLaughlin, J.K., Chow, W.H., Mandel, J.S., Mellemgaard, A., McCredie, M., Lindblad, P., Schlehofer, B., Pommer, W, Niwa, S. & Adami, H.-O. (1995) International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int. J. Cancer, 63, 216-221
42. Medical Products Agency (2000) Uppsala
43. Medicines Evaluation Board Agency (2000) The Hague
44. Mellemgaard, A., Niwa, S., Mehl, E.S., Engholm, G, McLaughlin, J.K. & Olsen, J.H. (1994) Risk factors for renal cell carcinoma in Denmark: Role of medication and medical history. Int. J. Epidemiol., 23, 923-930
45. Menard, R.H., Martin, H.F., Stripp, B., Gillette, J.R. & Bartter, F.C. (1974a) Spironolactone and cytochrome P-450: Impairment of steroid hydroxylation in the adrenal cortex. Life Sci., 15, 1639-1648
46. Menard, R.H., Stripp, B. & Gillette, J.R. (1974b) Spironolactone and testicular cytochrome P-450: Decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinol., 94, 1628-1636
47. Menard, R.H., Bartter, F.C. & Gillette, J.R. (1976) Spironolactone and cytochrome P-450: Impairment of steroid 21-hydroxylation in the adrenal cortex. Arch. Biochem. Biophys., 173, 395-402
48. Menard, R.H., Guenthner, T.M., Kon, H. & Gillette, J.R. (1979) Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7α-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450. J. biol. Chem., 254, 1726-1733
49. Miyakubo, H., Saito, S., Tokunaga, Y., Ando, H. & Nanba, H. (1977) [SC-14266 was administered intraperitoneally to pregnant rats and mice for the examination of pre- and post-natal development in their offspring.] Nichidai Igaku Zasshi, 36, 261-282 (in Japanese)
50. Mottino, A.D., Guibert, E.E. & Rodríguez Garay, E.A. (1989) Additive effect of combined spironolactone and phenobarbital treatment on hepatic bilirubin UDP-glucuronyltransferase. Biochem. Pharmacol., 38, 851-853
51. Mottino, A.D., Guibert, E.E. & Rodríguez Garay, E.A. (1991) Effect of spironolactone and phenobarbital administration on bilirubin glucuronidation in hepatic and extrahepatic rat microsomes. Biochem. Pharmacol., 41, 1075-1077
52. Nagi, S. & Virgo, B.B. (1982) The effects of spironolactone on reproductive functions in female rats and mice. Toxicol. appl. Pharmacol., 66, 221-228
53. National Agency for Medicines (2000) Helsinki
54. National Institute for Occupational Safety and Health (2000) National Occupational Exposure Sttirey 1981-83, Cincinnati, OH, Department of Health and Human Services, Public Health Service
55. Nielsen, B.B. (1990) Fibroadenomatoid hyperplasia of the male breast. Am. J. Surg. Pathol., 14, 774-777
56. Norwegian Medicinal Depot (2000) Oslo
57. Overdiek, H.W.P.M. & Merkus, F.W.H.M. (1987) The metabolism and biopharmaceutics of spironolactone in man. Rev. Drug Metab. Drug Interactions, 5, 273-302
58. Overdiek, H.W.P.M., Hermans, W.A. & Merkus, F.W.H.M. (1985) New insights into the pharmacokinetics of spironolactone. Clin. Pharmacol. Ther., 38, 469-474
59. Pita, J.C., Jr, Lippman, M.E., Thompson, E.B. & Loriaux, D.L. (1975) Interaction of spironolactone and digitalis with the 5 alpha-dihydrotestosterone (DHT) receptor of rat ventral prostate. Endocrinology, 97, 1521-1527
60. Rifka, S.M., Pita, J.C., Vigersky, R.A., Wilson, Y.A. & Loriaux, D.L. (1978) Interaction of digitalis and spironolactone with human sex steroid receptors. J. clin. Endocrinol. Metab., 46, 338-344
61. Ron, E., Kleinerman, R.A., Boice, J.D., Jr, LiVolsi, V.A., Flannery, J.T. & Fraumeni, J.F., Jr (1987) A population-based case-control study of thyroid cancer. J. natl Cancer Inst., 79, 1-12
62. Royal Pharmaceutical Society of Great Britain (2000) Martindale, The Extra Pharmacopoeia, 13th Ed., London, The Pharmaceutical Press [MicroMedex Online]
63. Sadée, W., Dagcioglu, M. & Schröder, R. (1973) Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J. Pharmacol. exp. Ther., 185, 686-695
64. Sadée, W., Schröder, R., Leitner, E.V. & Dagcioglu, M. (1974a) Multiple dose kinetics of spironolactone and canrenoate-potassium and cardiac and hepatic failrue. Eur. J. clin. Pharmacol., 7, 195-200
65. Sadée, W., Abshagen, U., Finn, C. & Rietbrock, N. (1974b) Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Arch. Pharmacol., 283, 303-318
66. Selby, J.V., Friedman, GD. & Fireman, B.H. (1989) Screening prescription drugs for possible carcinogenicity: Eleven to fifteen years of follow-up. Cancer Res., 49, 5736-5747
67. Selye, H., Mécs, I. & Savoie, L. (1969) Inhibition of anesthetics and sedative actions by spironolactone. Anesthesiology, 31, 261-264
68. Selye, H., Taché, Y. & Szabo, S. (1971) Interruption of pregnancy by various steriods. Fertil. Steril., 22, 735-740
69. Semler, D.E., Chengelis, C.P. & Radzialowski, P.M. (1989) The effects of chronic ingestion of spironolactone on serum thyrotropin and thyroid hormones in the male rat. Toxicol. appl. Pharmacol., 98, 263-268
70. Shapiro, J.A., Williams, M.A., Weiss, N.S., Stergachis, A., LaCroix, A.Z. & Barlow, W.E. (1999) Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am. J. Epidemiol., 149, 521-530
71. Sherry, J.H., O'Donnell, J.P., Flowers, L., LaCagnin, L.B. & Colby, H.D. (1986) Metabolism of spironolactone by adrenocortical and hepatic microsomes: Relationship to cytochrome P-450 destruction. J. Pharmacol. exp. Ther., 236, 675-680
72. Sherry, J.H., Johnson, P.B. & Colby, H.D. (1988) Species differences in adrenal spironolactone metabolism: Relationship to cytochrome P-450 destruction. Biochem. Pharmacol., 37, 355-357
73. Shuck, J., Shen, S., Owensby, L., Leftik, M. & Cucinell, S. (1981) Spironolactone hepatitis in primary hyperaldosteronism. Ann. intern. Med., 95, 708-710
74. Smals, A.G.H., Kloppenborg, P.W.C., Hoefnagels, W.H.L. & Drayer, J.I.M. (1979) Pituitary-thyroid function in spironolactone treated hypertensive women. Ada endocrinol., 90, 577-584
75. Society of Japanese Pharmacopoeia (1996) The Japanese Pharmacopoeia JP XIII, 13th Ed., Tokyo, pp. 639-640
76. Spanish Medicines Agency (2000) Madrid
77. Stierer, M., Spoula, H. & Rosen, H.R. (1990) [Breast cancer in the male -A retrospective analysis of 15 cases.] Onkologie, 13, 128-131 (in German)
78. Stricker, B.H.Ch. & Oei, T.T. (1984) Agranulocytosis caused by spironolactone. Br. med. J., 289, 731
79. Sutler, J.L. & Lau, E.P.K. (1975) Spironolactone. Anal. Profiles Drug Subst., 4, 431-451
80. Swiss Pharmaceutical Society, ed. (2000) Index Nonunion, International Drug Directory, 16th Ed., Stuttgart, Medpharm Scientific Publishers [MicroMedex Online]
81. Thompson, D.F. & Carter, J.R. (1993) Drug-induced gynecomastia. Pharmacotherapy, 13, 37-45
82. US Pharmacopeial Convention (1999) The 2000 US Pharmacopeia, 24th Rev./The National Formulary, 19th Rev., Rockville, MD, pp. 1546-1547
83. Weinman, S., Glass, A.G, Weiss, N.S., Psaty, B.M., Siscovick, D.S. & White, E. (1994) Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am. J. EpidemioL, 140, 792-804
84. Whitling, A.M., Pérgola, P.E., Sang, J.L. & Talbert, R.L. (1997) Spironolactone-induced agranulocytosis. Ann. Pharmacother., 31, 582-585
85. Yuan, J.-M., Castelao, J.E., Gago-Dominguez, M., Ross, R.K. & Yu, M.C. (1998) Hypertension, obesity and their medications in relation to renal cell carcinoma. Cancer, 77, 1508-1513